One of the biggest decisions in the life of any biotech is whether to
keep a promising compound in-house and market it directly, or whether to
partner with a larger pharmaceutical company and collect royalties.
While there have been a number of notable go-it-alone success stories
(including names like Alexion Pharmaceuticals (ALXN), Gilead (GILD), and Amgen (AMGN)),
there have also been multiple of examples of companies that essentially
shortchanged themselves by marketing a compound on their own.
Continue here to the full article:
Should The Amylin Example Discourage Amarin Shareholders?
No comments:
Post a Comment